Venetoclax for chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

Record ID 32016000410
Authors' objectives: Chronic lymphocytic leukaemia is a cancer that affects white blood cells called lymphocytes. It causes the body to make large numbers of abnormal lymphocytes that do not work properly and build up in the lymph nodes (glands) and bone marrow. Chronic lymphocytic leukaemia usually affects older people and usually develops slowly. However, the disease develops more quickly and is harder to treat in patients when the lymphocyte cells have certain mutations in their genes called 17p deletion or TP53 mutation. Venetoclax is a new drug for patients with chronic lymphocytic leukaemia with the 17p deletion or TP53 mutation, and it is given as a tablet once a day. If venetoclax is licensed for use in the UK, it could be a new treatment option for patients with chronic lymphocytic leukaemia that may reduce symptoms of the disease and increase survival.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Sulfonamides
  • Bridged Bicyclo Compounds, Heterocyclic
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Antineoplastic Agents
Organisation Name: NIHR Horizon Scanning Centre
Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
Contact Email:
Copyright: NIHR Horizon Scanning Centre (NIHR HSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.